Article Text

Download PDFPDF

Original research
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
  1. Catherine Overed-Sayer1,
  2. Elena Miranda2,
  3. Rebecca Dunmore3,
  4. Elena Liarte Marin3,
  5. Lorea Beloki3,
  6. Doris Rassl4,
  7. Helen Parfrey4,
  8. Alan Carruthers3,
  9. Amina Chahboub3,
  10. Sofia Koch2,
  11. Gülin Güler-Gane5,
  12. Michael Kuziora6,
  13. Arthur Lewis2,
  14. Lynne Murray1,
  15. Richard May3,
  16. Deborah Clarke3
  1. 1Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  2. 2Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom
  3. 3Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  4. 4Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, UK
  5. 5Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Cambridge, United Kingdom
  6. 6Translational Science, Early Oncology, Oncology Bioinformatics, AstraZeneca, Gaithersburg, Maryland, USA
  1. Correspondence to Dr Catherine Overed-Sayer, Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, United Kingdom; catherine.overed-sayer{at}astrazeneca.com

Abstract

Background Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease which presents a grave prognosis for diagnosed patients. Nintedanib (a triple tyrosine kinase inhibitor) and pirfenidone (unclear mechanism of action) are the only approved therapies for IPF, but have limited efficacy. The pathogenic mechanisms of this disease are not fully elucidated; however, a role for mast cells (MCs) has been postulated.

Objectives The aim of this work was to investigate a role for MCs in IPF and to understand whether nintedanib or pirfenidone could impact MC function.

Methods and results MCs were significantly elevated in human IPF lung and negatively correlated with baseline lung function (FVC). Importantly, MCs were positively associated with the number of fibroblast foci, which has been linked to increased mortality. Furthermore, MCs were increased in the region immediately surrounding the fibroblast foci, and co-culture studies confirmed a role for MC–fibroblast crosstalk in fibrosis. Nintedanib but not pirfenidone inhibited recombinant stem cell factor (SCF)–induced MC survival. Further evaluation of nintedanib determined that it also inhibited human fibroblast-mediated MC survival. This was likely via a direct effect on ckit (SCF receptor) since nintedanib blocked SCF-stimulated ckit phosphorylation, as well as downstream effects on MC proliferation and cytokine release. In addition, nintedanib ablated the increase in lung MCs and impacted high tissue density frequency (HDFm) in a rat bleomycin model of lung fibrosis.

Conclusion Nintedanib inhibits MC survival and activation and thus provides a novel additional mechanism by which this drug may exert anti-fibrotic effects in patients with IPF.

  • idiopathic pulmonary fibrosis
  • hypersensitivity pneumonitis
  • innate immunity
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CO-S designed and performed the research, analysed the data and wrote the manuscript; EM, RD, ELM, LB, DR, HP, AC, AC, SK and GG-G performed the research; EM provided critical input to histological assessments; HP and DR provided critical input to study cohort design; MK conducted bioinformatic analyses; AL co-ordinated histopathological assessments; LM, RM and DC planned the project and conceived the experiments. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests At the time of this study, all authors apart from DR, HP and SK were employees of MedImmune (part of the AstraZeneca group). DC is now an employee of Galapagos. CO-S, LM, AL, SK, GG-G and ELM are current AstraZeneca employees and have stock/stock options in AstraZeneca, and CO-S and LM are developing drugs for IPF.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available on reasonable request. Additional gene expression data are available on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.